Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial
2017 ASTRO Annual MeetingJeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).
Related Videos
Juanita Crook, MD, on Prostate Cancer: Results From an NRG/RTOG Brachytherapy Trial
Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer af...
Bhishamjit S. Chera, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV-16: Expert Perspective
Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation ther...
Shulian Wang, MD, and Benjamin Movsas, MD, on Breast Cancer: Radiation Therapy After Mastectomy
Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after ma...
Christopher R. Kelsey, MD, on DLBCL: Study Results on Consolidation Radiotherapy
Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II fi...
James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects
James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4)....
